SCHEMBL5373232

SCHEMBL5373232

Cc1cccc(CNC2Cc3ccccc3C2)c1

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.58
BACE1 P56817 1/20 0.58
BCHE P06276 1/20 0.56
GRIN2B Q13224 6/20 0.54
FYN P06241 1/20 0.54
SIGMAR1 Q99720 1/20 0.47
DRD2 P14416 2/20 0.46
DRD3 P35462 1/20 0.46
ALDH1A1 P00352 2/20 0.43
CYP2D6 P10635 1/20 0.43
OPRM1 P35372 1/20 0.42
OPRD1 P41143 1/20 0.42
OPRK1 P41145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10446669 0.98 ACHE (0.57) ACHEBACE1BCHEGRIN2BFYN
SCHEMBL1036268 0.83 ACHE (0.68) ACHEBACE1BCHEGRIN2BALDH1A1
Hydrochloric Acid SCHEMBL12813443 0.81 ACHE (0.67) ACHEBACE1BCHEGRIN2BALDH1A1
SCHEMBL5358231 0.81 GRIN2B (0.58) ACHEBACE1BCHEGRIN2BFYN
SCHEMBL3834622 0.81 GRIN2B (0.77) ACHEBACE1BCHEGRIN2BFYN
SCHEMBL5361993 0.81 KDM1A (0.55) GRIN2BFYNSIGMAR1DRD2DRD3
SCHEMBL3455685 0.81 FYN (0.62) GRIN2BFYNSIGMAR1DRD2DRD3
SCHEMBL5365488 0.80 ALDH1A1 (0.69) GRIN2BFYNDRD2ALDH1A1
SCHEMBL14492271 0.80 ACHE (0.65) ACHEBACE1BCHEALDH1A1
SCHEMBL14492276 0.80 ACHE (0.65) ACHEBACE1BCHEALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291621-B2 Substituted biaryl amides C5a receptor modulators NEUROGEN CORPORATION (US) 2007-11-06 US claimed
US-20060178414-A1 Substituted biaryl amides as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2006-08-10 US claimed
EP-1487796-A4 SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS NEUROGEN CORP (US) 2005-11-16 EP claimed
EP-1487796-A1 SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2004-12-22 EP claimed
US-20040048913-A1 Substituted biaryl amides as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2004-03-11 US claimed
WO-2003082826-A1 SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2003-10-09 WO claimed
US-7291621-B2 Substituted biaryl amides C5a receptor modulators NEUROGEN CORPORATION (US) 2007-11-06 US disclosed
US-7148225-B2 Substituted biaryl amides as C5A receptor modulators NEUROGEN CORPORATION (US) 2006-12-12 US disclosed
US-20060178414-A1 Substituted biaryl amides as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2006-08-10 US disclosed
US-20050096358-A1 Substituted biaryl amides as C5A receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048913-A1 Substituted biaryl amides as C5a receptor modulators C5AR1, C5AR2, C3AR1 ACHE 2569/4885BACE1 1467/4885BCHE 832/4885
US-20050096358-A1 Substituted biaryl amides as C5A receptor modulators C5AR1, C5AR2, C3AR1 ACHE 2431/4885BACE1 1535/4885BCHE 736/4885
US-20060178414-A1 Substituted biaryl amides as C5a receptor modulators C5AR1, C5AR2, C3AR1 ACHE 2431/4885BACE1 1535/4885BCHE 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.